Carl Icahn didn't amass a net worth of an estimated $16.6 billion by making dumb moves. So when Dow Jones reported that the billionaire bought a stake in Bristol-Myers Squibb (NYSE: BMY), it captured the attention of the investment …
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks …
NEW YORK -- Bristol-Myers Squibb Co. shares plunged nearly 7 percent Tuesday on concerns its earnings and dividend are in serious jeopardy now that a generic version of its best-selling medicine has been launched by Apotex Corp. …
Bristol-Myers Co. disclosed plans Thursday to acquire Squibb Corp. in a stock transaction currently valued at about $11.5 billion. If completed, the giant deal would continue the consolidation in the worldwide pharmaceutical industry. It also …
Bristol-Myers Squibb Co. (NYSE: BMY ... For the full year, analysts are expecting EPS of $3.23 and revenues of $21.38 billion. The stock traded down about 0.4% at $63.28 about an hour after Monday’s opening bell. The 52-week trading …
Bristol-Myers Squibb Co. shares edged up in premarket electronic trading today after a Goldman Sachs analyst upgraded the drug maker's stock because of its declining price. Bristol-Myers shares have been trading at annual lows over the …
Today's Daily Dose brings you news about Arena's progress in phase II study of Etrasimod in ulcerative colitis; expanded FDA approval of Bristol-Myers' leukemia drug Sprycel; voluntarily delisting of Mylan's ordinary shares from the Tel Aviv …